SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crow with knife community is actively hyping the project as a premier multichain meme coin with a built-in burn mechanism. Investors are discussing potential growth and new website updates while emphasizing the project's expansion across different blockchain networks.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing a sharp sell-off following a disappointing Q4 sales outlook and concerns over persistent weakness in the Chinese market, despite reporting a double beat on earnings. The community remains deeply divided, with many retail investors expressing frustration over the company's direction and brand relevance, while bargain hunters and contrarians debate whether the current price levels represent a generational buying opportunity or a signal of further long-term decline.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched Tema Space Innovators ETF ($NASA) is sparking intense debate among investors, with many traders attracted to its potential as a high-volatility play, while others express skepticism over its low assets under management and limited private company holdings. Community members are actively comparing the fund to similar space-themed vehicles and debating its exposure to SpaceX, creating a split sentiment between those looking for early-stage momentum and those wary of the ETF's structure.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is drawing significant investor interest as the community weighs upcoming Q1 delivery figures, with many anticipating strong performance due to high EV demand amid rising energy costs. While some retail investors remain bullish on long-term expansion, battery-swapping milestones, and potential profitability, the stock continues to face intense debate and volatility from short-sellers regarding consistent margins and market valuation.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is experiencing intense volatility driven by severe geopolitical instability in the Middle East and spiking oil prices, which have triggered aggressive short-term trading and hedging activity. Market participants are intensely debating whether the recent price action marks a capitulation or a temporary relief rally, while many traders utilize the current instability to execute rapid scalping strategies and accumulate positions during dips.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for community discussions as it faces significant price volatility and touches new lows, prompting intense debate between long-term "hodlers" maintaining conviction in its technology and skeptics questioning the project's viability. Market sentiment is heavily divided between those seeking bargain entry points based on institutional partnerships and those exiting due to concerns over management, staff reductions, and stagnant network activity compared to broader crypto sector performance.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is seeing heightened volatility as investors weigh conflicting geopolitical headlines regarding Iran against a series of analyst downgrades ahead of the upcoming Q1 delivery report. Community sentiment remains deeply divided, with some traders aggressively positioning for a potential short squeeze fueled by quarter-end window dressing, while others express caution over the company's valuation and the broader impact of ongoing macroeconomic instability.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The SPY is trending as traders weigh an aggressive market rally against uncertainty surrounding an upcoming national address from the President regarding the ongoing conflict in Iran. Community sentiment is deeply divided, with some investors betting on a de-escalation while many others remain skeptical, citing continued military deployments, rising oil prices, and concerns that the recent surge is merely a temporary bull trap.

Ganymede

Ganymede is gaining traction as community members highlight its stable price structure and deliberate accumulation phase as indicators of potential upward momentum. Investors are actively discussing the token's steady progression and disciplined market behavior, viewing the current setup as an opportunity to build positions before further volatility.

Invesco QQQ Trust Series 1 - Units of beneficial interest

The stock is currently experiencing extreme volatility driven by conflicting signals regarding the war in the Middle East, with traders attempting to navigate a speculative rally fueled by reports of potential peace negotiations. The market sentiment remains deeply divided, as community participants debate whether the recent gains represent a genuine reversal or a tactical trap fueled by end-of-quarter window dressing and unsubstantiated headlines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>An exposure-response analysis showed a statistically significant link between higher drug exposure and increased toxicities as well as more frequent treatment interruptions and discontinuations, the company said.</li><li>ORIC said it plans to launch its global late stage trial in metastatic castration-resistant prostate cancer patients who were previously treated with abiraterone using the 400 mg dose in the first half of 2026.</li></ul>Shares of ORIC Pharmaceuticals, Inc. (ORIC) fell 25% after hours on Tuesday after the company announced that it has selected a 400 mg once-daily dose of its investigational drug for a later stage trial after tolerability concerns emerged during an early stage study.In the early-stage trial involving certain previously treated patients with metastatic castration-resistant prostate cancer, the higher 600 mg dose of rinzimetostat produced a “modestly higher rate of adverse events and dose modifications” compared with the 400 mg level when administered with darolutamide, the company said.An exposure-response analysis showed a statistically significant link between higher drug exposure and increased toxicities as well as more frequent treatment interruptions and discontinuations, favoring the lower dose on safety grounds, it added.At the selected 400 mg dose, a grade 3 treatment-related adverse event was observed though the majority were mild, Oric said. Grade 3 treatment-related adverse events are severe, significant toxicities that are not immediately life-threatening. The company also reported one discontinuation in the early-stage &nbsp;trial. However, the company CEO Jacob M. Chacko said that the drug demonstrated a "cleaner safety profile than competitor regimens."ORIC said it plans to launch its global late stage trial in metastatic castration-resistant prostate cancer patients who were previously treated with abiraterone using the 400 mg dose in the first half of 2026. &nbsp;“Early efficacy data… are suggestive of meaningful and durable clinical benefit for rinzimetostat in combination with darolutamide compared to competitor data and historical outcomes with approved therapies,” the company said.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ORIC stock jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/ORIC">ORIC stock </a>has gained 127% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/omer-stock-surges-after-hours-on-novo-nordisk-deal-windfall-drug-launch-optimism/cZE5fIyRIVy">OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Oric Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses

The company noted that a higher dose of its experimental cancer drug was associated with a higher rate of adverse events in an early-stage trial. 

Equity

<ul class="summary-bullets"><li>Biogen stated Apellis shareholders will also receive two contingent value rights as part of the all-cash deal.</li><li>This entitles Apellis shareholders to receive two payments of $2 per share, contingent on Syfovre meeting certain annual global net sales thresholds.</li><li>Biogen stated that the Apellis acquisition will add two commercialized medicines in differentiated immunology and rare diseases to its growth portfolio: Empaveli and Syfovre.</li></ul>Apellis Pharmaceuticals Inc. (APLS) shares soared 140% in Tuesday’s pre-market trade after Biogen Inc. (BIIB) announced that it has agreed to acquire the company in a $5.6 billion deal.Biogen stated that the acquisition of Apellis will bolster its rare-disease treatment portfolio and accelerate its expansion into nephrology.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/APLS">Apellis Pharmaceuticals</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.<a href="https://stocktwits.com/symbol/APLS">Biogen shares</a> were down nearly 3% at the time of writing.Biogen stated that Apellis shareholders will also receive two contingent value rights (CVRs) as part of the all-cash deal, entitling the holder to receive two payments of $2 per share, contingent on certain annual global net sales thresholds for Syfovre being met.<h2 class="st-heading-2">What Does Apellis Bring To The Table?</h2>Biogen stated that the Apellis acquisition will add two commercialized medicines in differentiated immunology and rare diseases to its growth portfolio: Empaveli and Syfovre.Syfovre is the first and only FDA-approved therapy for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The regulator approved Empaveli in 2025 as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients aged 12 years and older.<h2 class="st-heading-2">Biogen Highlights Revenue, Earnings Boost From Apellis Acquisition</h2>Biogen stated that Empaveli and Syfovre will boost its topline immediately, noting that these two treatments achieved combined net sales of $689 million in 2025 and expect them to grow in the mid-to-high teens at least through 2028.“Consistent with our strategy, this acquisition immediately advances Biogen’s ongoing transformation. The addition of Apellis expands our growth portfolio in immunology and rare disease with two approved, best-in-class medicines that complement our existing portfolio and bolsters our near-and long-term growth potential,” said Biogen CEO Christopher A. Viehbacher.The company added that the Apellis acquisition is expected to be increasingly accretive to Biogen’s diluted earnings per share (EPS) starting in 2027. Biogen stated that it plans to update the full-year 2026 guidance when it reports its first-quarter (Q1) earnings.<a href="https://stocktwits.com/symbol/APLS">APLS stock</a> is down 32% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> is up 7%. The S&amp;P Biotech ETF (XBI) is up 41% over the past 12 months, while the Vanguard Small-Cap Index Fund ETF (VB) is up 15%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/artl-bfrg-hkit-stocks-top-premarket-gainers-march-31-2026/cZEPAT9RIV2">ARTL, BFRG, HKIT Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a trending stock chart.

APLS Stock Soars 140% Today – Here’s Everything To Know About Apellis' Massive $5.6B Deal With Biogen

Biogen stated that the acquisition of Apellis will bolster its rare-disease treatment portfolio and accelerate its expansion into nephrology.

<ul class="summary-bullets"><li>Founder Patrick Soon-Shiong signaled balance sheet “strengthening” and a push for global expansion.</li><li>Soon-Shiong had also flagged Europe expansion talks around “immunotherapy 2.0.”</li><li>Momentum has eased over the past week after an FDA warning letter over claims suggesting Anktiva could treat cancers beyond its approved use.</li></ul>Shares of ImmunityBio, Inc. (IBRX) climbed more than 2% overnight early Tuesday after founder Patrick Soon-Shiong teased balance sheet “strengthening” and global expansion plans, as short sellers stepped back amid strong momentum for Anktiva, its lead immunotherapy.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> plunged nearly 10% on Monday, but is on track to post its best quarter in about six years. Shares have surged 237% so far this year, outperforming the SPDR S&amp;P Biotech ETF (XBI), which has dipped nearly 3% over the same period.&nbsp;&nbsp;<h2 class="st-heading-2">Founder Teases Balance Sheet Strengthening&nbsp;</h2>Soon-Shiong&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2038800665481552070">took to X</a> on Tuesday and said, “Strengthening the balance sheet. Recharging for global expansion. Stay tuned.”The development comes&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-breakout-quarter-anektiva-long-covid-europe-expansion/cZERi1sRIZL">just a day</a> after Soon-Shiong signaled the company’s European expansion plans, saying he had been invited by a European health minister to discuss advancing “immunotherapy 2.0.” The effort is part of a broader push to expand natural killer cell- and CD8 T-cell-based therapies, which are immune treatments that activate the body’s virus- and cancer-fighting cells, alongside Anktiva’s global rollout.<h2 class="st-heading-2">Short Bets Retreat From Highs</h2>Meanwhile, short interest in IBRX has been steadily declining from&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-became-high-stakes-showdown-between-shorts-and-retail-bulls/cZRjSn9R4w4">record highs</a> hit in mid-February, as sentiment improved following regulatory approvals and continued expansion of Anktiva across new indications and geographies.Short positioning rose to 13.7% of the free float between Feb.13 and Feb.19, according to Koyfin data, as investors awaited a final decision from the European Commission on approval of the therapy for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ with or without papillary tumors.The uncertainty eased later in February after the European Commission granted conditional marketing authorization across 27 European Union member states plus Iceland, Liechtenstein and Norway, expanding Anktiva’s reach to 33 countries globally, including the U.S.Short interest declined to 13.1% by Feb. 27, marking its first drop since October 2025, and has since eased further to around 12.9%. The drop followed a slew of developments supporting the therapy’s outlook beyond its initial bladder cancer indication. These include the launch of a Phase 2 study evaluating Anktiva in long COVID, expansion into programs across non-small cell lung cancer, pancreatic cancer, colorectal cancer and glioblastoma, and new trials in severe pneumonia, sepsis and acute respiratory distress syndrome.Momentum was also supported by NCCN guideline inclusion for papillary bladder cancer that no longer responds to standard BCG therapy, the company’s resubmission seeking label expansion into papillary disease, and preparations for a Saudi Arabia launch following approvals covering bladder cancer and metastatic non-small cell lung cancer.<h2 class="st-heading-2">FDA Warning Weighs On Shares</h2>The improving sentiment follows a sharp selloff over the past week after the U.S. Food and Drug Administration (FDA) issued a warning letter to ImmunityBio and Soon-Shiong, citing false and misleading promotional claims about Anktiva.The agency objected to statements in a television advertisement and a podcast appearance suggesting the therapy could treat cancers beyond its approved bladder cancer indication, including claims that it “can treat all cancers.” The FDA said the representations implied uses not supported by the drug’s labeling and requested corrective action within 15 working days.The warning came after regulators had refused to review the company’s application seeking broader label expansion, prompting ImmunityBio to resubmit it earlier this month.<h2 class="st-heading-2">How Do Stocktwits Users Feel About IBRX?</h2>On Stocktwits, retail sentiment slipped to ‘bearish’ from ‘bullish’ levels a day ago amid over a 400% surge in message volumes over the past 24 hours.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_png_7c546e0d33.webp" alt="ibrx.png" width="970" height="143"><figcaption>IBRX sentiment and message volume as of March 31 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/BePositive1/message/649012988">said</a> Soon-Shiong could strengthen the balance sheet by boosting assets or reducing liabilities. They added that with 650 million shares and voting control, a buyout near $20 billion could cost about $7 billion, calling the idea “genius,” and said “there are a lot of players who would want a large piece of this like Elon or the Saudi’s.”<stembedurl>https://stocktwits.com/BePositive1/message/649012988</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Regener8/message/649012939">said</a>, “I’m guessing it will be $200-250 million dollars, otherwise it wouldn’t really do much strengthening. That post is annoyingly cryptic, although I think he meant it as a comfort to long shareholders and a discomfort for shorts.”<stembedurl>https://stocktwits.com/Regener8/message/649012939</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uso-batl-tpet-slide-overnight-on-signs-iran-crisis-may-be-ending-analysts-say-war-premium-fading-but-supply-risks-remain/cZEPj9HRINH">USO, BATL, TPET Slide Overnight On Signs Iran Crisis May Be Ending: Analysts Say War Premium Fading, But Supply Risks Remain</a>

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Gains Steam: Founder Teases Balance Sheet ‘Strengthening’ And Global Push As Bears Finally Step Back

IBRX Stock - Short interest eased to about 12.9% from a record 13.7% amid Anktiva's expansion into long COVID, multiple cancers, pneumonia, sepsis and ARDS trials.

Short interest eased to about 12.9% from a record 13.7% amid Anktiva's expansion into long COVID, multiple cancers, pneumonia, sepsis and ARDS trials.

<ul class="summary-bullets"><li>Viridian stated that the REVEAL-1 trial showed strong results, meeting its main goal and a key secondary goal at week 24 as measured by eye bulging.</li><li>The company stated that Elegrobart reduced eye bulging by about 54% in the four-week regimen and by 63% in the eight-week regimen, compared with roughly 18% on placebo.</li><li>Viridian stated that topline results from REVEAL-2, the second Phase 3 trial evaluating Elegrobart in patients with chronic thyroid eye disease, are expected in the second quarter of 2026.</li></ul>Viridian Therapeutics Inc. (VRDN) shares tanked more than 41% in Monday’s pre-market trade after the company announced results from its Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease.Viridian stated that the REVEAL-1 trial of Elegrobart met its primary endpoint of proptosis responder rate (PRR) with a highly statistically significant treatment effect in the four-week dosing regimen.However, the company stated that while Elegrobart was generally well tolerated in the four and eight-week dosing regimens, the phase 3 trial showed low rates of hearing impairment.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/VRDN">Viridian Therapeutics</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Did The Trial Reveal?</h2>Viridian stated that the REVEAL-1 trial showed strong results, meeting its main goal and a key secondary goal at week 24 as measured by eye bulging. The study also tested a different dosing schedule (every 8 weeks) versus placebo and examined other important outcomes.The company stated that Elegrobart reduced eye bulging by about 54% in the four-week regimen and by 63% in the eight-week regimen, compared with roughly 18% on placebo.However, Elegrobart showed only a slight improvement over placebo in the Clinical Activity Score (CAS), a measure of inflammation and disease activity.Viridian’s results showed that the CAS reduction to 0 or 1 was 57% in the four-week regimen and 69% in the eight-week regimen, compared with 50% in the placebo group.The company said that all complaints of adverse events in both regimens were reports of tinnitus, none of which were associated with hearing reduction.<h2 class="st-heading-2">Viridian Says Elegrobart On Track For BLA Submission In 2027</h2>The company stated that topline results from REVEAL-2, the second Phase 3 trial evaluating Elegrobart in patients with chronic thyroid eye disease, are expected in the second quarter (Q2) of 2026.Following this, Viridian plans to submit a Biologics License Application (BLA) to the U.S. FDA in Q1 2027. A BLA is a formal request submitted to the U.S. Food and Drug Administration (FDA) asking for approval to sell a biologic drug.<a href="https://stocktwits.com/symbol/VRDN">VRDN stock</a> is down 12% year-to-date, but up 87% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 40% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 19%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/roma-stock-soars-100m-share-repurchase-program/cZERVIhRIZs">ROMA Stock Shot Up 10% Today – Everything To Know About Its Gigantic Share Repurchase Program</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

VRDN Stock Plummeted 41% Pre-Market Today — What Did Its Phase 3 Active Thyroid Eye Disease Trial Reveal?

Viridian stated that while Elegrobart was generally well tolerated in the four and eight-week dosing regimens, the phase 3 trial showed low rates of hearing impairment.

Dr. Patrick Soon-Shiong arrives at Trump National Golf Club Bedminster in Bedminster Township, N.J. on Saturday, Nov. 19, 2016. (Photo by Jabin Botsford/The Washington Post via Getty Images)

IBRX Stock Eyes Breakout Quarter: Anktiva Enters Phase 2 Long COVID Trial As Europe Expansion Plans Emerge

Founder Patrick Soon-Shiong said he was invited by a European health minister to discuss expanding “immunotherapy 2.0”, signaling potential expansion of Anktiva.

<ul class="summary-bullets"><li>The average 12-month price target on the stock is $18, representing a potential upside of as much as 495% from the stock’s current $3.02 trading levels.</li><li>The company is currently looking forward to initiating a late-stage trial of pemvidutide in MASH in 2026.</li><li>Truist believes that pemvidutide "could be successful in treating MASH as well as liver-related diseases AUD."</li></ul>Shares of Altimmune (ALT) traded 5% lower on Friday despite Wall Street viewing a potential upside of as much as 495% on the stock.According to data from Koyfin, nine of the 11 analysts covering the stock rate it ‘Buy’ or higher while one rates it ‘Hold’ and one has a ‘Sell’ rating on the shares.The average 12-month price target on the stock is $18, compared to the stock’s current $3.02 trading levels.<h2 class="st-heading-2">Wall Street Take</h2>Earlier this month, Truist initiated coverage of Altimmune with a ‘Buy’ rating and $12 price target. The firm believes that the company's lead candidate pemvidutide "could be successful in treating MASH."Truist is modelling peak 20,000 patients on pemvidutide, which would result in worldwide "peak adjusted/unadjusted revenue of ~$600million/$1.0billion," it said.<h2 class="st-heading-2">Altimmune Pipeline</h2>Altimmune is a clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH). The company’s pemvidutide is in development for the treatment of alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in addition to MASH.The company is currently looking forward to initiating a late-stage trial of pemvidutide in MASH in 2026. The trial is expected to evaluate multiple pemvidutide doses over a 52-week treatment period.The company is looking forward to announcing topline data from a mid–stage trial of pemvidutide in Alcohol Use Disorder in the third quarter of 2026, and is also enrolling patients into a mid-stage trial of the drug in Alcohol-associated Liver Disease.<h2 class="st-heading-2">Retail Sentiment</h2>On Stocktwits, retail sentiment around ALT stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.A Stocktwits user expressed disappointment about the stock’s downward trajectory.<stembedurl>https://www.stocktwits.com/Moemazon/message/648788986</stembedurl><a href="https://stocktwits.com/symbol/ALT">ALT stock</a> has dropped 45% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rckt-stock-dives-despite-gene-therapy-approval-wall-street-dismisses-sell-off/cZ3HfqIRImh">RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Altimmune logo is seen displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?

According to data from Koyfin, nine of the 11 analysts covering the stock rate it ‘Buy’ or higher while one rates it ‘Hold’ and one has a ‘Sell’ rating on the shares.

<ul class="summary-bullets"><li>Viking is developing VK2735 in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.</li><li>The company stated that the primary endpoint of the Phase 3 VANQUISH-2 study is the percentage change in body weight from baseline for participants receiving VK2735.</li><li>The company stated it expects to complete the VANQUISH studies in 2027.</li></ul>Viking Therapeutics Inc. (VKTX) on Thursday announced that it has completed enrollment in the Phase 3 trial of its obesity drug, VK2735, which is in the race to compete in the GLP-1 obesity drug market, dominated by Novo Nordisk's Ozempic and Wegovy.The company said that the Phase 3 VANQUISH-2 study will assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.Viking is developing VK2735 in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.<a href="https://stocktwits.com/symbol/VKTX">Viking Therapeutics shares</a> were up nearly 2% in Thursday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory.<h2 class="st-heading-2">What Are The Primary And Secondary Endpoints?</h2>Viking Therapeutics stated that the primary endpoint of the Phase 3 VANQUISH-2 study is the percentage change in body weight from baseline for participants receiving VK2735, compared to patients on placebo after 78 weeks of treatment.The secondary and exploratory endpoints include an evaluation of several efficacy and safety measures. This includes the percentage of patients who achieve 5%, 10%, 15% and 20% or more body weight reduction during the trial.“As with the VANQUISH-1 study, we are happy to see a study of this size enroll quickly, which we believe speaks to the enthusiasm for new obesity treatments beyond those currently available,” said Viking CEO Brian Lian.The company stated it expects to complete the VANQUISH studies in 2027.<h2 class="st-heading-2">Phase 3 Trial Update</h2>Viking also announced an update regarding its Phase 3 VANQUISH-1 study of subcutaneous VK2735 in patients who have obesity or are overweight.The company also stated that it is evaluating VK2735 in a Phase 1 study evaluating a range of potential maintenance dosing regimens. Results from the maintenance study are expected in the third quarter (Q3) of 2026.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> is down 6% year-to-date, but up 19% over the past 12 months. The S&amp;P Biotech ETF (XBI) is up 42% over the past 12 months, while the Vanguard Small-Cap Growth Index Fund ETF (VBK) is up 18%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-iran-begging-for-deal-warns-get-serious-on-talks-dow-futures-fall/cZ3ru8hRIjM">Trump Says Iran ‘Begging’ For Deal, Warns Them To 'Get Serious’ On Talks — Dow Futures Fall More Than 300 Points</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress

The company said that the Phase 3 VANQUISH-2 study will assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.

<ul class="summary-bullets"><li>Cantor noted that, even though Adma Biologics released a statement following the short report, the firm expected more specific feedback addressing the direct claims made in the report.</li><li>Cantor analyst Kristen Kluska also cited a lack of clarity and concerns around increased days sales outstanding and accounts receivable for downgrading Adma Biologics.</li><li>ADMA stock has declined nearly 29% since Culper’s short report was released on Tuesday.</li></ul>Adma Biologics Inc. (ADMA) has been downgraded by analysts at Cantor Fitzgerald, with the firm citing disappointment among investors following the company’s response to a short report.According to TheFly, Cantor stated that its discussions with several investors pointed to a lack of direct communication from Adma Biologics after Culper Research released its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/adma-stock-drops-after-culper-research-alleges-channel-stuffing/cZ3nq7uRI1i">short report</a> on Tuesday.Cantor downgraded Adma Biologics to ‘Neutral’ from ‘Overweight’ without a price target. ADMA stock has declined nearly 29% since Culper’s short report was released.<a href="https://stocktwits.com/symbol/ADMA">Adma Biologics’ shares</a> were down more than 2% in Thursday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">What Is Cantor Concerned About?</h2>Cantor noted that, even though Adma Biologics released a statement following the short report, the firm expected more specific feedback addressing the direct claims made in the report.Cantor analyst Kristen Kluska also cited a lack of clarity and concerns around increased days sales outstanding and accounts receivable for downgrading Adma Biologics.According to Koyfin, the average 12-month price target for ADMA stock is $23.5, implying a return potential of 144% from current levels. Of the three analyst ratings, two have a ‘Buy’ recommendation, while one has a ‘Hold’ rating.<h2 class="st-heading-2">What Did The Short Report Flag?</h2>Culper Research stated in its short report that Adma Biologics’ sales growth is driven by a “de facto channel stuffing scheme.” The firm stated that Adma’s revenue declined 3% in 2025, after adjusting for sales inflation, while the company reported a 20% growth.The short seller also noted that the sales of Adma’s flagship product, Asceniv, have been inflated by 40% to 76%. “We believe the ASCENIV growth story is total fiction owing entirely to channel stuffing,” Culper added.The firm added that, based on its interactions with two high-level employees at one of Adma’s largest distributors, the biopharmaceutical company induced the distributor to stock excess Asceniv by offering rebates and extended payment terms to meet the distributor's order expectations.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One user on the platform stated that even if a part of Culper’s short report is true, it gives the company a black eye.<stembedurl>https://stocktwits.com/Tradeswithyourmom/message/648578343</stembedurl>However, a bullish user dismissed the short report, saying that there is nothing to see here.<stembedurl>https://stocktwits.com/glacier64/message/648588280</stembedurl><a href="https://stocktwits.com/symbol/ADMA">ADMA stock</a> is down 47% year-to-date and 52% over the past 12 months. The iShares Core S&amp;P Small-Cap ETF (IJR) is up 17% over the past 12 months, while the S&amp;P Biotech ETF (XBI) is up 42%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iran-us-ceasefire-plan-maximalist-unreasonable-white-house-weekend-talks/cZ3YvQ5RISH">Iran Reportedly Says US Ceasefire Proposal Is 'Extremely Maximalist And Unreasonable' Even As White House Plans Weekend Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ADMA Biologics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ADMA Stock Downgraded By Cantor As ‘Channel Stuffing’ Claims Shake Investor Confidence

Cantor stated that its discussions with several investors pointed to a lack of direct communication from Adma Biologics after Culper Research released its short report on Tuesday.

<ul class="summary-bullets"><li>Anavex stated it withdrew the application for blarcamesine after the EMA’s Committee for Medicinal Products for Human Use indicated that it would not issue a positive opinion for the company’s Alzheimer’s drug at this time.</li><li>The company added that it filed the blarcamesine application following guidance from the EMA’s small and medium-sized enterprises office to move forward with marketing authorization preparations.</li><li>This comes two days after Anavex reported new data about blarcamesine, suggesting a slowdown in brain shrinkage.</li></ul>Anavex Life Sciences Corp. (AVXL) shares tanked more than 33% in Wednesday’s opening trade after the company announced that it has withdrawn its marketing authorization application for its Alzheimer’s drug, blarcamesine, in the European Union.Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.This comes two days after Anavex&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/avxl-stock-soars-anavex-alzheimers-drug-blarcamesine-slows-brain-shrinkage/cZ3mhyrRI0F">reported</a> new data about blarcamesine, suggesting a slowdown in brain shrinkage.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/AVXL">Anavex Life Sciences</a> trended in the ‘extremely bullish’ territory at the time of writing.<h2 class="st-heading-2">Why Did Anavex Withdraw Application?</h2>Anavex stated that it withdrew the application for blarcamesine after the EMA’s Committee for Medicinal Products for Human Use indicated that it would not issue a positive opinion for the company’s Alzheimer’s drug at this time.The company added that it filed the blarcamesine application following guidance from the EMA’s small and medium-sized enterprises (SMEs) office to move forward with marketing authorization preparations.“Anavex now has to take note of the differing assessment of the CHMP at the EMA and will consider the constructive feedback received from the CHMP and focus on gathering additional data and conducting further analyses to address the points raised by the CHMP,” the company stated.<h2 class="st-heading-2">New Blarcamesine Trial Data Suggests Slowdown In Brain Shrinkage</h2>Earlier this week, Anavex reported new data about blarcamesine, suggesting a slowdown in brain shrinkage. Brain shrinkage is a key marker of Alzheimer’s progression.At the AD/PD 2026 Conference, Anavex presented new data on blarcamesine from its Phase IIb and Phase III programs, indicating that preservation of brain volume is associated with improved patient outcomes.The company said its trial data suggest patients with wild-type SIGMAR1 and COL24A1 genes may see greater clinical and structural benefits from blarcamesine.MRI biomarker analysis showed a strong and consistent link between reduced brain atrophy and improvements in cognition, daily activities, and overall clinical outcomes, Anavex said.<a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> is down 21% year-to-date and 71% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 43% over the past 12 months, while the iShares Biotechnology ETF (IBB) is up 25%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lmt-stock-lockheed-martin-quadruple-precision-strike-missiles-production-iran-war/cZ3YFRyRIS9">Lockheed Martin To Quadruple Precision Strike Missile Output After First Combat Use In Iran War</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

AVXL Stock Tanks After Anavex Withdraws EU Bid For Alzheimer's Drug

Anavex stated that the decision to withdraw the application follows feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

SPDR Series Trust - State Street SPDR S&P Biotech ETF

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

Current Price	$126.96
Prev Close	$118.78
Open	$122.94
Dividend Yield	N/A
50-Day Moving Average	$125.07
Beta	N/A
Avg. Volume	8.8M
PE Ratio	N/A

52-Week High	$132.09
52-Week Low	$66.66
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

XBI
SPDR S&P Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XBI News

XBISPDR S&P Biotech ETF